Perioperative pembrolizumab demonstrates clinical benefit in locally advanced HNSCC Summary Perioperative pembrolizumab, combining neoadjuvant and adjuvant immunotherapy around surgery, shows promising clinical benefit in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). Read More